Search research articles
Contact Us
Filters
Showing results (61-70 of 101) with videos related to
Page
of 11
Sort By:
American Journal of Clinical Oncology
|
April 16, 1998
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889)
J D Berlin, K J Propert, D Trump, et al.
Journal of the National Cancer Institute
|
August 19, 1999
Low-dose difluoromethylornithine and polyamine levels in human prostate tissue
E M Messing, R R Love, K D Tutsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2000
Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial
S Fields-Jones, A Koletsky, G Wilding, et al.
Cancer Research
|
September 1, 1995
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response
S M Planchon, S Wuerzberger, B Frydman, et al.
Journal of the National Cancer Institute
|
May 5, 1993
Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine
R R Love, P P Carbone, A K Verma, et al.
Cancer Investigation
|
October 19, 2000
Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer
B Kasimis, G Wilding, W Kreis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2001
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin
C Mundhenke, J P Thomas, G Wilding, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1992
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions
H Bailey, G Wilding, K D Tutsch, et al.
Cancer Research
|
July 1, 1991
Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice
G Zugmaier, S Paik, G Wilding, et al.
Journal of Cellular Physiology
|
November 1, 1989
Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines
G Zugmaier, B W Ennis, B Deschauer, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 101) with videos related to
Sort By:
Page
of 11
American Journal of Clinical Oncology
|
April 16, 1998
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889)
J D Berlin, K J Propert, D Trump, et al.
Journal of the National Cancer Institute
|
August 19, 1999
Low-dose difluoromethylornithine and polyamine levels in human prostate tissue
E M Messing, R R Love, K D Tutsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2000
Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial
S Fields-Jones, A Koletsky, G Wilding, et al.
Cancer Research
|
September 1, 1995
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response
S M Planchon, S Wuerzberger, B Frydman, et al.
Journal of the National Cancer Institute
|
May 5, 1993
Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine
R R Love, P P Carbone, A K Verma, et al.
Cancer Investigation
|
October 19, 2000
Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D2) prostate cancer
B Kasimis, G Wilding, W Kreis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 14, 2001
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin
C Mundhenke, J P Thomas, G Wilding, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1992
A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions
H Bailey, G Wilding, K D Tutsch, et al.
Cancer Research
|
July 1, 1991
Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice
G Zugmaier, S Paik, G Wilding, et al.
Journal of Cellular Physiology
|
November 1, 1989
Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines
G Zugmaier, B W Ennis, B Deschauer, et al.
Page
of 11